Loading analysis...
Nu Skin's Doubling Narrative Amid an Asset Discount and Revenue Decline
Show original post
TL;DR: Nu Skin trades at a ~$234M market cap with $251.8M of net working capital, $379.6M of PP&E, and essentially zero net debt. You're getting the real estate, the factories, and the brand for less than free. There's an unfilled daily gap from Feb 13 up to $9.78 - which is still a 5% discount to tangible book. Yes it's an MLM. Yes revenue is falling.
The balance sheet (6/30/26 10-Q, ~48.55M shares out)
- Cash + ST investments: $190.0M - that's $3.91/share, roughly 81% of the stock price sitting in cash
- Total current assets $508.2M vs total current liabilities $256.4M → net working capital of $251.8M, or $5.19/share
- Stock is at $4.82
Stop there for a second. Net working capital per share ($5.19) is above the share price ($4.82). Graham-style. Current assets net of all current liabilities exceed the entire market cap by ~$18M, and you haven't counted a single hard asset yet.
- PP&E, net: $379.6M ($7.82/share) - the Provo campus, manufacturing, distribution
- LT debt: $193.7M against $190.0M cash → net debt ≈ $4M. Not levered. Not a bankruptcy candidate.
- Total equity $542.7M ($11.18/share). Strip goodwill ($4.8M) and intangibles ($37.9M) → tangible book $500.1M = $10.30/share
P/B ≈ 0.43. P/TBV ≈ 0.47. P/S ≈ 0.17. It still pays a $0.24 dividend (~5.0% yield) covered by $0.70-$0.90 of guided adjusted EPS.
The chart
Daily gap from Feb 13 remains unfilled up to $9.78. The stock has not traded into that zone in eight months. Gap fill from $4.82 = +103%. And the punchline: $9.78 is still 5% below the $10.30 tangible book. You'd double your money and the thing would still be trading at a discount to liquidation-ish value.
The bear case, because I'm not going to pretend it isn't ugly
- Book value is actively melting. Equity went $794M → $542.7M in ONE quarter (Q2'26). Goodwill $83.6M → $4.75M - management wrote off 94% of it. If you bought this thesis in April at $7, you got run over by the balance sheet you were underwriting. It can happen again.
- Revenue is in structural decline. Q2'26 revenue $320.1M, -17.1% YoY. FY guidance cut from $1.35-1.50B to $1.28-1.35B. EPS guide cut from $0.80-1.20 to $0.70-0.90. This is an MLM: fewer sales leaders → less revenue → fewer sales leaders. It's reflexive and it does not obviously stop.
- The inventory number is the soft spot. $191.5M of inventory is the biggest chunk of that working capital. It's skincare and supplements with expiration dates, for a demand base shrinking 17% a year. In any real liquidation you're haircutting that hard. The $5.19 NWC/share is a book number, not a realizable one.
- PP&E is illiquid. $380M is mostly a purpose-built corporate campus in Utah. Worth book only if someone wants it.
- China. Material revenue exposure to a market with ongoing regulatory and sentiment risk toward direct selling.
What would actually make me wrong (in a good way)
Revenue decline decelerating to single digits. Q3 prints in early November - guidance was $310-340M. A print at the high end with stabilizing sales leader counts is the thing to watch.
Position: 11,500 shares across three brokerages
Not financial advice. I'm a guy on the internet who read a 10-Q.
The OP presents an asset-discount recovery thesis for Nu Skin (NUS), rather than a growth story: using the post's share price of $4.82 and approximately 48.55 million shares, market capitalization is approximately $234 million, below net working capital of $251.8 million, leading the OP to argue that the real estate, factories, and brand are effectively being thrown in for free. Citing the second-quarter 2026 balance sheet, the OP lists approximately $190 million in cash and short-term investments, $508.2 million in current assets, and $256.4 million in current liabilities, deriving cash per share of $3.91 and net working capital per share of $5.19. The OP also adds $379.6 million in net fixed assets to emphasize asset backing. For valuation, the OP subtracts goodwill and intangible assets from $542.7 million in equity to arrive at approximately $500.1 million in tangible book value, or $10.30 per share, corresponding to a P/B of approximately 0.43x, P/TBV of approximately 0.47x, and P/S of approximately 0.17x. The OP further supports the holding-return narrative with an annualized dividend of $0.24, a dividend yield of approximately 5%, and adjusted EPS guidance of $0.70–$0.90. The technical target is a $9.78 gap on the daily chart that the OP claims was left on February 13, 2026: approximately 103% upside from $4.82, while still approximately 5% below the OP's calculated tangible book value. However, the post has no attached chart, and the image links in the comments provide no discernible content, so neither the gap nor proof of the position can be confirmed from those materials. The OP reports holding a total of 11500 shares across three brokerage accounts, worth approximately $55.43 thousand at the price cited in the post, without disclosing the cost basis or the position's share of account assets. The OP also acknowledges value-trap risk: second-quarter equity fell from approximately $794 million to $542.7 million, with a substantial goodwill write-down; quarterly revenue was $320.1 million, down 17.1% year over year, full-year revenue guidance was lowered to $1.28–$1.35 billion, and adjusted earnings guidance was also reduced. The OP believes the MLM model may enter a self-reinforcing cycle of declining sales leader numbers and shrinking revenue, that $191.5 million in skincare and nutritional supplement inventory faces markdown risk, that purpose-built campuses and factories may be difficult to sell at book value, and that the China business faces additional regulatory and demand risks. The anticipated catalyst is third-quarter earnings, which the OP expects in early November, with attention on whether revenue approaches the upper end of the $310–$340 million guidance range, whether the decline narrows to single digits, and whether sales leader numbers stabilize; the specific release date has not been verified. The core implicit assumptions are that business deterioration will slow before the asset cushion is exhausted and that the market will again recognize the value of the balance-sheet assets. The most important flaw is that net working capital subtracts only current liabilities and is not the liquidation residual after deducting all debt, much less proof that hard assets are free; the OP's near-zero net debt calculation also omits $20 million in debt due within one year, bringing net debt on a comprehensive basis to approximately $22.28 million. Tangible book value is likewise not liquidation value; prepaid expenses, other assets, and disposal costs still require scrutiny, and filling a gap does not itself guarantee a price recovery. Key verification evidence is provided in fact_check below.
There are 6 comments, providing too small a sample of substantive discussion, with no meaningful support for or rebuttal of the asset valuation or revenue-decline thesis. The highest-scoring comment asks for proof of the position, and the OP replies "Updated," corresponding to the added shareholding disclosure in the post, but the available materials cannot verify brokerage account documentation. The remaining expressions of agreement, jokes about the author's hobbies, and indiscernible image links do not constitute community endorsement of the investment thesis.
Loading Truth Social...
Loading live updates...